Birdwatch Note
2023-03-13 13:45:16 UTC - NOT_MISLEADING
"Under section 564 of the Federal Food, Drug, and Cosmetic Act...FDA may authorize unapproved medical products when certain criteria are met, including there are no adequate, approved, and available alternatives." https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
Written by A6B7C94D607680D99973341C540FAC49F6C676A835BFBAD0BF1FF7A114A5E595
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1634338660270108677
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1635275837271605251
- noteId - 1635275837271605251
- participantId - A6B7C94D607680D99973341C540FAC49F6C676A835BFBAD0BF1FF7A114A5E595
- noteAuthorParticipantId -
- createdAtMillis - 1678715116218
- tweetId - 1634338660270108677
- classification - NOT_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 1
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- "Under section 564 of the Federal Food, Drug, and Cosmetic Act...FDA may authorize unapproved medical products when certain criteria are met, including there are no adequate, approved, and available alternatives." https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2023-03-13 13:45:16 UTC (1678715116218) |
1969-12-31 23:59:59 UTC (-1) |
2023-03-15 05:09:59 UTC (1678856999448) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
| rated at | rated by | |
| 2023-03-14 21:14:48 -0500 | Rating Details | |
| 2023-03-14 15:08:39 -0500 | Rating Details | |
| 2023-03-14 01:28:13 -0500 | Rating Details | |
| 2023-03-14 00:25:17 -0500 | Rating Details | |
| 2023-03-13 22:34:47 -0500 | Rating Details | |
| 2023-03-13 22:17:36 -0500 | Rating Details | |
| 2023-03-13 19:59:38 -0500 | Rating Details | |
| 2023-03-13 15:00:51 -0500 | Rating Details | |
| 2023-03-13 13:35:32 -0500 | Rating Details | |
| 2023-03-13 12:43:13 -0500 | Rating Details | |
| 2023-03-13 12:16:20 -0500 | Rating Details | |
| 2023-03-13 11:17:47 -0500 | Rating Details | |
| 2023-03-13 11:04:58 -0500 | Rating Details | |
| 2023-03-13 09:29:32 -0500 | Rating Details | |
| 2023-03-13 09:12:40 -0500 | Rating Details | |
| 2023-03-15 16:22:24 -0500 | Rating Details | |
| 2023-03-15 15:08:52 -0500 | Rating Details | |
| 2023-03-15 12:01:00 -0500 | Rating Details | |
| 2023-03-15 01:50:59 -0500 | Rating Details | |
| 2023-03-14 23:56:08 -0500 | Rating Details | |
| 2023-03-14 23:38:06 -0500 | Rating Details | |
| 2023-03-16 16:22:13 -0500 | Rating Details | |
| 2023-03-16 14:57:21 -0500 | Rating Details | |
| 2023-03-16 13:22:02 -0500 | Rating Details | |
| 2023-03-16 00:38:41 -0500 | Rating Details | |
| 2023-03-17 09:32:46 -0500 | Rating Details | |
| 2023-03-17 06:49:26 -0500 | Rating Details | |
| 2023-03-18 23:51:15 -0500 | Rating Details | |
| 2023-03-20 12:25:31 -0500 | Rating Details | |
| 2023-03-20 12:15:41 -0500 | Rating Details | |
| 2023-03-30 10:51:14 -0500 | Rating Details | |
| 2023-04-29 17:26:25 -0500 | Rating Details | |
| 2023-03-15 01:50:59 -0500 | Rating Details | |
| 2023-04-29 17:26:25 -0500 | Rating Details | |
| 2023-03-16 13:22:02 -0500 | Rating Details | |
| 2023-03-13 09:12:40 -0500 | Rating Details | |
| 2023-03-30 10:51:14 -0500 | Rating Details | |
| 2023-03-20 12:15:41 -0500 | Rating Details | |
| 2023-03-18 23:51:15 -0500 | Rating Details | |
| 2023-03-15 12:01:00 -0500 | Rating Details | |
| 2023-03-14 01:28:13 -0500 | Rating Details | |
| 2023-03-17 06:49:26 -0500 | Rating Details | |
| 2023-03-13 13:35:32 -0500 | Rating Details | |
| 2023-03-14 00:25:17 -0500 | Rating Details | |
| 2023-03-13 15:00:51 -0500 | Rating Details | |
| 2023-03-13 09:29:32 -0500 | Rating Details | |
| 2023-03-13 11:04:58 -0500 | Rating Details | |
| 2023-03-14 15:08:39 -0500 | Rating Details | |
| 2023-03-16 00:38:41 -0500 | Rating Details | |
| 2023-03-16 16:22:13 -0500 | Rating Details | |
| 2023-03-14 23:56:08 -0500 | Rating Details | |
| 2023-03-13 12:16:20 -0500 | Rating Details | |
| 2023-03-13 19:59:38 -0500 | Rating Details | |
| 2023-03-15 15:08:52 -0500 | Rating Details | |
| 2023-03-16 14:57:21 -0500 | Rating Details | |
| 2023-03-13 22:17:36 -0500 | Rating Details | |
| 2023-03-13 22:34:47 -0500 | Rating Details | |
| 2023-03-13 11:17:47 -0500 | Rating Details | |
| 2023-03-17 09:32:46 -0500 | Rating Details | |
| 2023-03-13 12:43:13 -0500 | Rating Details | |
| 2023-03-20 12:25:31 -0500 | Rating Details | |
| 2023-03-14 23:38:06 -0500 | Rating Details | |
| 2023-03-14 21:14:48 -0500 | Rating Details | |
| 2023-03-15 16:22:24 -0500 | Rating Details | |
| 2023-07-12 14:42:48 -0500 | Rating Details |